These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 3003298)

  • 1. Naloxone does not modify the antihypertensive effect of captopril in essential hypertensive patients.
    Bernini G; Taddei S; Graziadei L; Pedrinelli R; Salvetti A
    J Hypertens Suppl; 1985 Nov; 3(2):S117-9. PubMed ID: 3003298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The captopril test--an aid in the detection of scarring nephropathy as a cause of arterial hypertension in children].
    Peco-Antić A; Nastić-Mirić D; Babić D; Kostić M
    Srp Arh Celok Lek; 1999; 127(9-10):305-11. PubMed ID: 10649899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone does not antagonize the antihypertensive effect of chronic captopril therapy in hypertensive patients.
    Bernini GP; Lucarini AR; Vivaldi MS; Del Corso C; Lenzi M; Salvetti A
    Cardiovasc Drugs Ther; 1989 Dec; 3(6):829-33. PubMed ID: 2487544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A discrepancy between the effects of a single oral dose of captopril on blood pressure, plasma renin activity, and serum angiotensin-converting enzyme levels.
    Lechi A; Covi G; Capuzzo MG; Lechi C; Minuz P; Delva P; Scuro LA
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):569-74. PubMed ID: 6317579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive activity of captopril (SQ 14,225), an orally active inhibitor of angiotensin converting enzyme in conscious two-kidney perinephritic hypertensive dogs.
    Vollmer RR; Boccagno JA; Steinbacher TE; Horovitz ZP; Murthy VS
    J Pharmacol Exp Ther; 1981 Feb; 216(2):225-31. PubMed ID: 6257882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of food intake on pharmacodynamics and plasma concentration of captopril.
    Müller HM; Overlack A; Heck I; Kolloch R; Stumpe KO
    J Hypertens Suppl; 1985 Nov; 3(2):S135-6. PubMed ID: 3910768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
    Jackson EK; Dubinion JH; Mi Z
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of inhibition of converting enzyme by captopril on arterial pressure, renin and aldosterone in essential hypertension].
    Posadas C; Sánchez G; Boyer JL; Delmar M; Serrano PA
    Arch Inst Cardiol Mex; 1982; 52(4):295-300. PubMed ID: 6291470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension.
    Azizi M; Guyene TT; Chatellier G; Ménard J
    J Hypertens; 1994 Apr; 12(4):419-27. PubMed ID: 8064166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of acute haemodynamic response to high-dose naloxone in young hypertensive and normotensive humans.
    Hara K; Senn BM; Floras JS
    Clin Invest Med; 1995 Apr; 18(2):108-13. PubMed ID: 7788955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension.
    Bauer IH; Reams GP; Wu Z; Lau-Sieckman A
    J Hum Hypertens; 1995 Apr; 9(4):237-43. PubMed ID: 7595905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of plasma endothelin-1 concentration by captopril in patients with essential hypertension.
    Uemasu J; Munemura C; Fujihara M; Kawasaki H
    Clin Nephrol; 1994 Mar; 41(3):150-2. PubMed ID: 8187357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
    Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of naloxone on muscle sympathetic nerve activity, systemic and calf haemodynamics and ambulatory blood pressure after exercise in mild essential hypertension.
    Hara K; Floras JS
    J Hypertens; 1995 Apr; 13(4):447-61. PubMed ID: 7629406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Age dependence of the response of blood pressure, heart rate and plasma renin activity to captopril in essential hypertension].
    Stanek B; Silberbauer K
    Acta Med Austriaca; 1984; 11(3-4):101-5. PubMed ID: 6089491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors in hypertension: a review.
    Salvetti A; Pedrinelli R; Arzilli F; Abdel-Haq B; Magagna A; Lucarini A; Graziadei L; Nuccorini A; Taddei S
    Int J Clin Pharmacol Res; 1985; 5(6):429-38. PubMed ID: 3005182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral and haemodynamic interactions between clonidine and nifedipine in human essential hypertension.
    Stornello M; Pedrinelli R; Valvo E; Scapellato L; Salvetti A
    J Hypertens Suppl; 1985 Dec; 3(3):S227-9. PubMed ID: 2856710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of naloxone to reduce the clonidine induced reduction of blood pressure and plasma noradrenaline in patients with essential hypertension.
    Bramnert M; Hökfelt B
    Acta Physiol Scand; 1983 Aug; 118(4):379-83. PubMed ID: 6314747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems.
    Ohman KP; Karlberg BE; Nilsson OR; Wettre S
    Acta Med Scand Suppl; 1981; 646():98-105. PubMed ID: 7018190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Captopril and opiate antagonism in essential hypertension.
    Ajayi AA; Rubin PC; Reid JL
    Br J Clin Pharmacol; 1986 May; 21(5):543-5. PubMed ID: 3521691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.